Subtype
Malignant Hepatobiliary Neoplasm
CI-CAN-00001136Explore in graph →
1,160 active trials17 approved drugs42 evidence items
- NCIt
- C8609
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001136Explore in graph →
Clinical trials
5,029 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (561)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04149691 | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | unknown | Phase 1 | 42 | Celon Pharma SAINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05173298 | Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab(HCC) | unknown | — | 100 | CHA UniversityOTHER | 1 | Feb 7, 2024 |
| clinicaltrials |
| NCT06247293 | Surgical Resection Combined With Intraperitoneal Hyperthermic Chemotherapy | unknown | — | 100 | Zhujiang HospitalOTHER | 0 | Feb 7, 2024 | clinicaltrials |
| NCT06031818 | Usability and Clinical Effectiveness of an Interpretable Deep Learning Framework for Post-Hepatectomy Liver Failure Prediction | unknown | — | 80 | Maastricht UniversityOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06244446 | Efficacy and Safety of SBRT Combined With Atezolizumab Plus Bevacizumab vs Atezolizumab Plus Bevacizumab in Treating Unresectable Advance Hepatocellular Carcinoma. | unknown | — | 40 | Institute of Liver and Biliary Sciences, IndiaOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT04161287 | Comparison of Efficacy in SBRT of HCC ≤5 cm With or Without TACE | unknown | — | 330 | Beijing 302 HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT04560894 | SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma(HCC) | unknown | Phase 2 / Phase 3 | 405 | Sinocelltech Ltd.INDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT06232538 | UCAD for Diagnosing Benign or Malignant Gallbladder Diseases and Follow-up | unknown | — | 1 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT04682847 | Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers | unknown | — | 40 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06233994 | A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma | unknown | N/A | 30 | Changsha Taihe HospitalOTHER_GOV | 1 | Jan 31, 2024 | clinicaltrials |
| NCT05062837 | Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC | unknown | Phase 2 / Phase 3 | 62 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05711823 | Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC | unknown | Phase 3 | 300 | Guangxi Medical UniversityOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT05910970 | Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation(PREVENT-2) | unknown | Phase 3 | 200 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06182644 | Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant Tumors(FAPI) | unknown | N/A | 30 | Guangdong Provincial People's HospitalOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT04224480 | Longitudinal Immune-phenotyping of HCC Following MK-3475 | unknown | Phase 1 | 8 | National Cancer Centre, SingaporeOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT05293158 | Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma - a Proof of Concept Study(HBIG) | unknown | N/A | 5 | Medical University of GrazOTHER | 0 | Jan 18, 2024 | clinicaltrials |
| NCT04800497 | The Role Of Circulating Tumor Cells As Markers Of Advanced Disease And Prognosis In HCC | unknown | — | 70 | University of Milano BicoccaOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT05962450 | Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy | unknown | Phase 2 | 84 | Beijing YouAn HospitalOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06205732 | A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer. | unknown | — | 100 | Qianfoshan HospitalOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT05021250 | SBRT With DIBH for HCC After TACE and Lipiodol Marking | unknown | N/A | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06192784 | Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma(CCGLC-012) | unknown | Phase 2 | 36 | Tongji HospitalOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06194695 | DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma(CCGLC-009) | unknown | — | 100 | Ze-yang Ding, MDOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05185531 | A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma(Notable-HCC) | unknown | Phase 1 | 20 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT02611453 | Cholangiography Using Carbon Dioxide Versus Iodinated Contrast in ERCP | unknown | N/A | 40 | University of VirginiaOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06178809 | Clinical Research on Dynamic Monitoring MRD Via Plasma ctDNA After Systemic Therapy of Hepatocellular Carcinoma | unknown | — | 475 | Singlera Genomics Inc.INDUSTRY | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06144385 | A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma | unknown | Phase 1 | 20 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 2, 2024 | clinicaltrials |
| NCT06182865 | A Study of Ga-68 Dolacga to Evaluate Liver Reserve Function in Patients With HCC Before and After Proton Therapy | unknown | N/A | 10 | National Atomic Research Institute, TaiwanOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04422249 | A Study of Laparoscopic Middle Hepatic Vein Guidance and Traditional Anatomic Hemihepatectomy | unknown | N/A | 95 | Southwest Hospital, ChinaOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT06181318 | Quantitative MRI and Outcomes of Liver Resection | unknown | — | 33 | University Hospital HeidelbergOTHER | 0 | Dec 26, 2023 | clinicaltrials |
| NCT06178926 | Ciprofol Sedation in Patients Undergoing Liver Cancer Percutaneous Radiofrequency Ablation | unknown | N/A | 80 | Zhejiang Cancer HospitalOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT04329429 | A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer | unknown | Phase 2 | 57 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 20, 2023 | clinicaltrials |
| NCT05031949 | Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma(CCGLC-003) | unknown | Phase 1 | 20 | Zhang Bi Xiang, MDOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05103007 | PVE/PVL Combined With DEB-TACE in the Treatment of Patients With Large and Unresectable Liver Cancer(CCGLC-004) | unknown | N/A | 200 | Tongji HospitalOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05520801 | Primary Hepatobiliary Cancer Cohort of Central China(CCGLC-002) | unknown | — | 2,000 | Tongji HospitalOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05533892 | Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC(CCGLC-007) | unknown | Phase 1 | 30 | Wan-Guang ZhangOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05839197 | A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC(CCGLC-010) | unknown | Phase 2 | 38 | Wan-Guang ZhangOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT04559607 | TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma | unknown | N/A | 188 | Zhongda HospitalOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT05845554 | Application of Chromosomal Instability in Early Diagnosis of Biliary Tract Carcinoma | unknown | — | 300 | Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical UniversityOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT05070156 | B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma | unknown | Early Phase 1 | 3 | Tongji UniversityOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT06171321 | Circulating Tumor DNA Guided Adjuvant Chemotherapy for Biliary Tract Carcinoma | unknown | N/A | 94 | Shanghai East HospitalOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT03839706 | Relationship Between 18FDG PET/MRI Patterns and ctDNA to Predict HCC Recurrence After Liver Transplantation(PETMRIinHCC) | unknown | N/A | 20 | University Health Network, TorontoOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT05820906 | Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT05429190 | Validation of SMS Protocol for HCC Screening in High-risk Patients | unknown | — | 470 | Erasmus Medical CenterOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05600803 | Screening Single-operator Cholangioscopy for Neoplastic Bile Duct Lesions | unknown | — | 236 | Soonchunhyang University HospitalOTHER | 1 | Nov 27, 2023 | clinicaltrials |
| NCT06146127 | Precision Medicine for Combined Hepatocellular-Cholangiocarcinoma(PREMED-CHC) | unknown | — | 300 | Inserm U955OTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05872828 | Cross-sectional Study of Chinese Liver Cancer Patients | unknown | — | 120 | The Nethersole School of NursingOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06134973 | A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC. | unknown | — | 1,000 | Tianjin Third Central HospitalOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06134193 | Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer | unknown | Phase 2 | 41 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Nov 18, 2023 | clinicaltrials |
| NCT06124001 | Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 36 | CNBG-Virogin Biotech (Shanghai) Ltd.INDUSTRY | 0 | Nov 15, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Feb 7, 2024source: clinicaltrials